Committed to a Cure

The VIC team
Vaccine & Immunotherapy Center staff located at the Charlestown Navy Yard, Boston, Massachusetts

In a unique collaboration, the Vaccine and Immunotherapy Center (VIC) works with medical and business professionals who understand each aspect of moving research from the lab to the clinic. VIC is committed to the support of cutting edge research initiatives to accelerate the development of the most promising cancer and infectious disease vaccines and immunotherapies.


According to forecasts by the National Cancer Institute and the Centers for Disease Control and Prevention, cancer is likely to replace heart disease as the leading cause of death for adults in the United States within the next few years. Moreover, infectious diseases such as influenza, typhoid, and cholera remain the most frequent causes of death for children worldwide. New therapies and vaccines are urgently needed to treat and prevent these diseases.


VIC is directed by Mark Poznansky, MD, PhD, an Associate Professor of Medicine at Harvard Medical School and Attending Physician in Infectious Diseases at Massachusetts General Hospital. In addition to Dr. Poznansky’s extensive research and clinical experience, VIC has an advisory board of medical, business and philanthropic leaders to guide researchers in the complicated process of vaccine and immunotherapy development.


VIC's single most important metric for success is the advancement of new technologies for patient care in the United States and abroad. Projects funded by the center are chosen based on their potential for genuine breakthrough and a realistic positive impact on patient care. VIC's unique, gated approach allows innovative treatments to move quickly through the pipeline. Scientists leading these projects receive unique mentorship, guidance and support from members of the VIC Advisory Board, who have been trained in diverse fields and have the highest level of expertise in discovery, product development, and delivery of vaccines and other novel therapies.


Current therapies being studied at VIC include a novel adjuvant to improve vaccine efficacy, new immune therapies to fight ovarian cancer, new self-assembling adjuvants for use with vaccines for infectious diseases including influenza, and a new method which uses encapsulation to protect transplanted insulin producing tissues for patients with Type I diabetes.


VIC has been supported by the outstanding generosity of philanthropists including members of the Croatti and Hill Families. VIC has also been successful in leveraging support from the NIH, DARPA, The Marsha Rivkin Ovarian Cancer Research Foundation and the Juvenile Diabetes Research Foundation. VIC is committed to raising an additional $5M to support the accelerated development of vaccines and immunotherapies for infectious diseases and cancer.

Back to Top